The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

BACKGROUND: Myocardial fibrosis is a multistep process, which results in collagen deposition in the injured muscle. Empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), decreases cardiovascular events risk. Little is known on the effects of empagliflozin in non-diabetic patients early...

Descripción completa

Detalles Bibliográficos
Autores principales: Daud, Elias, Ertracht, Offir, Bandel, Nadav, Moady, Gassan, Shehadeh, Monah, Reuveni, Tali, Atar, Shaul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254247/
https://www.ncbi.nlm.nih.gov/pubmed/34215277
http://dx.doi.org/10.1186/s12933-021-01322-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254247/
https://www.ncbi.nlm.nih.gov/pubmed/34215277
http://dx.doi.org/10.1186/s12933-021-01322-6

Ejemplares similares